Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
$20.85
+5.1%
$20.61
$13.30
$30.03
$1.18B0.93362,165 shs830,394 shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$19.61
+1.2%
$19.24
$13.22
$45.37
$1.12B-1.89922,813 shs544,304 shs
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.20
+2.6%
$1.02
$0.37
$1.31
$267.18M1.661.60 million shs723,110 shs
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$1.15
+3.6%
$0.66
$0.35
$1.95
$1.22B1.8576.17 million shs51.16 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
+5.09%+3.12%-6.71%+27.13%-11.91%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
+1.24%-2.53%+7.98%-20.12%-50.53%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
+2.56%0.00%+11.11%+71.75%+39.47%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
+3.60%+11.65%+56.23%+159.95%-39.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
2.8442 of 5 stars
3.52.00.00.02.44.20.0
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.4861 of 5 stars
3.53.00.00.01.41.70.6
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
2.7083 of 5 stars
3.51.00.00.02.53.30.6
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.6325 of 5 stars
3.11.00.00.03.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
3.00
Buy$41.2097.60% Upside
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
3.00
Buy$75.71286.10% Upside
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$4.25254.17% Upside
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2.20
Hold$1.9266.67% Upside

Current Analyst Ratings Breakdown

Latest LCTX, TLRY, ELVN, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$75.00 ➝ $60.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$92.00 ➝ $90.00
8/7/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$89.00 ➝ $87.00
8/5/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
7/29/2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
Zelman & Associates
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
7/2/2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$40.00 ➝ $48.00
6/23/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$65.00
6/23/2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$89.00
6/23/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
6/23/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/A$8.25 per shareN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$13.40 per shareN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$9.50M28.85N/AN/A$0.21 per share5.71
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
$821.31M1.54$0.15 per share7.68$1.40 per share0.82
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%N/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%N/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$18.61M-$0.12N/AN/AN/A-374.84%-20.00%-12.93%N/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$2.19B-$2.31N/AN/AN/A-265.69%-6.83%-5.45%10/9/2025 (Estimated)

Latest LCTX, TLRY, ELVN, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
-$0.53-$0.49+$0.04-$0.49N/AN/A
8/6/2025Q2 2025
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.28-$0.36-$0.08-$0.36N/AN/A
7/28/2025Q4 2025
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
-$0.03$0.02+$0.05-$1.30$250.41 million$224.54 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
N/A
32.58
32.58
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
20.48
20.48
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
4.08
4.08
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
0.20
2.46
1.49

Institutional Ownership

CompanyInstitutional Ownership
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
95.08%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
9.35%
CompanyEmployeesShares OutstandingFree FloatOptionable
Enliven Therapeutics, Inc. stock logo
ELVN
Enliven Therapeutics
5059.24 million43.89 millionOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13657.60 million54.37 millionOptionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
60228.36 million167.16 millionNot Optionable
Tilray Brands, Inc. stock logo
TLRY
Tilray Brands
2,8421.10 billion1.09 billionOptionable

Recent News About These Companies

Tilray Brands (NASDAQ:TLRY) Trading Down 3.3% - Time to Sell?
Logo visible on smartphone screen with website page
Tilray's High Hopes: The Catalyst Driving Cannabis Stocks
...
Top Cannabis Stocks To Watch Today - August 20th
Tilray Brands (NASDAQ:TLRY) Trading Down 7.5% - Time to Sell?
Cannabis Stocks To Follow Today - August 19th
Tilray cannabis
Tilray Shares Blazing: What's Behind the 55% Rally This Month?
...
Tilray Brands (NASDAQ:TLRY) Shares Gap Up - Here's Why
Cannabis Stocks Worth Watching - August 16th
Best Canadian Cannabis Stocks in 2025
Best Cannabis Stocks To Follow Today - August 15th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Enliven Therapeutics stock logo

Enliven Therapeutics NASDAQ:ELVN

$20.85 +1.01 (+5.09%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$20.88 +0.03 (+0.14%)
As of 08/22/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$19.61 +0.24 (+1.24%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$19.92 +0.32 (+1.61%)
As of 08/22/2025 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Lineage Cell Therapeutics stock logo

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.20 +0.03 (+2.56%)
Closing price 08/22/2025 04:10 PM Eastern
Extended Trading
$1.22 +0.02 (+1.67%)
As of 08/22/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Tilray Brands stock logo

Tilray Brands NASDAQ:TLRY

$1.15 +0.04 (+3.60%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.14 0.00 (-0.43%)
As of 08/22/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.